Ads
related to: medications for breast cancer patientsWorking to be "the most powerful patient advocate in America" - Forbes
Search results
Results from the WOW.Com Content Network
Breast cancer chemotherapy. A woman being treated with docetaxel chemotherapy for breast cancer. Cold mittens and wine chilling devices are placed on her hands and feet to prevent deleterious effects on the nails. Similar strategies can be used to prevent hair loss. Breast cancer chemotherapy refers to the use of cytotoxic drugs (chemotherapy ...
September 17, 2024 at 1:17 PM. The Food and Drug Administration expanded the approval of Kisqali, a drug for metastatic breast cancer, to also treat patients with earlier stages of the disease ...
Breast cancer management takes different approaches depending on physical and biological characteristics of the disease, as well as the age, over-all health and personal preferences of the patient. Treatment types can be classified into local therapy (surgery and radiotherapy) and systemic treatment (chemo-, endocrine, and targeted therapies).
Palbociclib, sold under the brand name Ibrance among others, is a medication developed by Pfizer for the treatment of HR -positive and HER2 -negative breast cancer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6. [5][6] Palbociclib was the first CDK4/6 inhibitor to be approved as a cancer therapy.
Tamoxifen is used for the treatment of both early and advanced estrogen receptor-positive (ER-positive or ER+) breast cancer in pre-and postmenopausal women. [23] Tamoxifen increases the risk of postmenopausal bleeding, endometrial polyps, hyperplasia, and endometrial cancer; using tamoxifen with an intrauterine system releasing levonorgestrel might increase vaginal bleeding after 1 to 2 years ...
Abemaciclib, sold under the brand name Verzenio among others, is a medication for the treatment of advanced or metastatic breast cancers. It was developed by Eli Lilly and it acts as a CDK inhibitor selective for CDK4 and CDK6. [4] It was designated as a breakthrough therapy for breast cancer by the US Food and Drug Administration (FDA) in ...
Aromatase inhibitors (AIs) are a class of drugs used in the treatment of breast cancer in postmenopausal women and in men, [1][2] and gynecomastia in men. They may also be used off-label to reduce estrogen conversion when supplementing testosterone exogenously. They may also be used for chemoprevention in women at high risk for breast cancer.
For example, breast cancer patients of fertile age oftentimes have to weigh the risks and benefits associated with starting an adjuvant therapy regimen after primary treatment. In the some low-risk, low-benefit situations, forgoing adjuvant treatment altogether can be a reasonable decision, but in cases where the risk of metastasis is high ...